AMH
HRTX icon

Apollo Management Holdings’s Heron Therapeutics HRTX Stock Holding History

Apollo Management Holdings’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-283,859
Closed -$2.08M – 374
2021
Q4 		$2.59M Buy
+283,859
New +$2.9M 0.01% 158

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Apollo Management Holdings's HRTX Position: Q1 2022 in Review

Apollo Management Holdings sold out of Heron Therapeutics (HRTX) in Q1 2022, closing a stake of 283,859 shares — an estimated $2.08M sold.

Apollo Management Holdings first reported a position in HRTX in Q4 2021 and held it in 1 quarter. The position peaked at $2.59M in Q4 2021. 186 funds tracked by Wall St. Rank hold HRTX as of Q1 2022.

  • Apollo Management Holdings reported no remaining Heron Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Apollo Management Holdings sold 283,859 Heron Therapeutics shares in Q1 2022, an estimated $2.08M.
  • Apollo Management Holdings first reported a position in Heron Therapeutics in Q4 2021 and held it in 1 quarter.
  • Apollo Management Holdings's Heron Therapeutics position peaked at $2.59M in Q4 2021.
  • 186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2022.

Based on Apollo Management Holdings's 13F filing for Q1 2022, filed 16 May 2022.